Whitehawk Therapeutics announced data showing SEZ6 protein is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors, exceeding other known targets. This supports their development of HWK-206, a next-generation antibody drug conjugate (ADC) designed to target SEZ6, with an Investigational New Drug application planned for mid-2026 and Phase 1 trials starting in Q3 2026. The findings highlight SEZ6's potential for effective treatment, especially in combination with DLL3-targeted therapies, offering hope for improved outcomes in difficult-to-treat cancers.
Precigen's PAPZIMEOS, the first FDA-approved therapy for recurrent respiratory papillomatosis (RRP), demonstrated durable complete responses in 83% of patients over at least 36 months without additional treatment. Five patients maintained responses b...
BioNTech and Bristol Myers Squibb announced encouraging interim Phase 2 results for pumitamig, a PD-L1xVEGF-A bispecific immunomodulator, combined with chemotherapy in untreated advanced non-small cell lung cancer (NSCLC). The ROSETTA Lung-02 trial s...
Computer engineer CharuSan argues XRP's potential $300 price is driven by integration into global banking infrastructure, not retail speculation. After regulatory clarity, XRP could be adopted system-wide via platforms like Volante Technologies, enab...
Hyperliquid (HYPE) surged past $67, reaching new all-time highs as strong buyer demand absorbed supply despite profit-taking by early investors. One major holder realized about $95 million in gains but still controls significant tokens, limiting supp...
ImPact Biotech presented updated positive data from its Phase 1 trial for Padeliporfin VTP in locally advanced pancreatic ductal adenocarcinoma (LA-PDAC) and Phase 3 ENLIGHTED trial in low-grade upper tract urothelial carcinoma (LG-UTUC) at ASCO 2026...
